Head-To-Head Survey: Travere Therapeutics (NASDAQ:TVTX) and SAB Biotherapeutics (NASDAQ:SABS)

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and Travere Therapeutics (NASDAQ:TVTX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares SAB Biotherapeutics and Travere Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SAB Biotherapeutics N/A -40.04% -35.98%
Travere Therapeutics -18.66% -185.69% -17.24%

Earnings & Valuation

This table compares SAB Biotherapeutics and Travere Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAB Biotherapeutics $1.32 million 191.78 $13.27 million ($1.33) -2.11
Travere Therapeutics $490.73 million 9.19 -$25.55 million ($1.29) -36.43

SAB Biotherapeutics has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

7.8% of SAB Biotherapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for SAB Biotherapeutics and Travere Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAB Biotherapeutics 1 1 9 0 2.73
Travere Therapeutics 1 1 11 0 2.77

SAB Biotherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 327.05%. Travere Therapeutics has a consensus price target of $72.55, indicating a potential upside of 54.37%. Given SAB Biotherapeutics’ higher possible upside, equities research analysts clearly believe SAB Biotherapeutics is more favorable than Travere Therapeutics.

Volatility and Risk

SAB Biotherapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Summary

SAB Biotherapeutics beats Travere Therapeutics on 7 of the 13 factors compared between the two stocks.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics is a biotechnology company developing antibody-based medicines for autoimmune and infectious diseases. Its platform uses genetically engineered cattle to produce fully human polyclonal antibodies, which the company evaluates as potential treatments. The company’s pipeline has included SAB-142, an investigational therapy being developed for type 1 diabetes. Earlier programs included antibody candidates targeting infectious diseases, such as influenza and COVID-19. SAB Biotherapeutics was founded in 2014 and is based in Sioux Falls, South Dakota.

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.